Equities

Travere Therapeutics Inc

TVTX:NMQ

Travere Therapeutics Inc

Actions
  • Price (USD)18.26
  • Today's Change0.40 / 2.24%
  • Shares traded905.93k
  • 1 Year change+223.19%
  • Beta0.6835
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy6
Outperform8
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 16 analysts offering 12 month price targets for Travere Therapeutics Inc have a median target of 24.50, with a high estimate of 42.00 and a low estimate of 15.00. The median estimate represents a 34.17% increase from the last price of 18.26.
High130.0%42.00
Med34.2%24.50
Low-17.9%15.00

Earnings history & estimates in USD

On Oct 31, 2024, Travere Therapeutics Inc reported 3rd quarter 2024 losses of -0.70 per share. This result was in line with the consensus of the 10 analysts following the company and under-performed last year's 3rd quarter results by -2.67.
The next earnings announcement is expected on Feb 13, 2025.
Average growth rate+7.41%
Travere Therapeutics Inc reported annual 2023 losses of -1.50 per share on Jan 08, 2024.
Average growth rate-5.37%
More ▼

Revenue history & estimates in USD

Retrophin, Inc. had 3rd quarter 2024 revenues of 62.90m. This bettered the 60.48m consensus of the 15 analysts covering the company. This was 10.36% above the prior year's 3rd quarter results.
Average growth rate+15.08%
Retrophin, Inc. had revenues for the full year 2023 of 145.24m. This was 31.50% below the prior year's results.
Average growth rate-2.62%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.